Tumor-specific antibody response induced by novel immunomodulator, IFx-Hu2.0, reflects extent of epitope spreading to multiple tumor epitopes
Anti‑tumor efficacy of plasmid encoding emm55 in a murine melanoma model
Trial in progress: IFx Hu2.0 (plasmid DNA coding for Emm55 streptococcal antigen in a cationic polymer) phase I first in human study for unresectable stage III or stage IV cutaneous melanoma
View PDF https://d1io3yog0oux5.cloudfront.net/_990f4fa3e396222b16458f9091bbe91c/morphogenesisinc/db/2306/20858/pdf/Markowitz_AACR_04122020_revised1+Amanda+Laubscher.pdf
View Article https://aacrjournals.org/cancerres/article/80/16_Supplement/CT241/645158/Abstract-CT241-Trial-in-progress-IFx-Hu2-0-plasmid
First in human Phase I study using a plasmid DNA coding for Emm55 streptococcal antigen (IFx-Hu2.0) in patients with unresectable stage III or stage IV cutaneous melanoma
View PDF https://d1io3yog0oux5.cloudfront.net/_990f4fa3e396222b16458f9091bbe91c/morphogenesisinc/db/2306/20857/pdf/AACR+2019+Markowitz_Morphogenesis_march192019JM-AD+Amanda+Laubscher.pdf
View Article https://aacrjournals.org/cancerres/article/79/13_Supplement/CT119/637715/Abstract-CT119-Trial-in-progress-First-in-human